|
Back to Home » February 2018 News » US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER |
US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER |
February 17, 2018
WILMINGTON, Del., Feb. 16, 2018 /PRNewswire/ -- AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has approved IMFINZI® (durvalumab) for the treatment of patients with unresectable Stage III...
Source URL: https://www.prnewswire.com/news-releases/us-fda-approves-imfinzi-durvalumab-for-unresectable-stage-iii-non-small-cell-lung-cancer-300600414.html
|
|
|
|
